Share this article Share this article BOSTON, Feb. 17, 2021 /PRNewswire/ -- The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute's eRapid technology with the company's proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications. The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with GBS’s transistor technology in developing a multiplexed COVID-19 biomarker diagnostic. Credit: Wyss Institute at Harvard University